Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06366217
PHASE4

Efficacy of the MydCombi on Pupillary Dilation in Pediatric and Adult Patients

Sponsor: University of California, San Francisco

View on ClinicalTrials.gov

Summary

To raise the standard of care, improve the overall patient experience and streamline practice flow, Eyenovia has developed an innovative mydriatic to be delivered as a microdose by a specialized dispenser. While still achieving effective pupil dilation, MydCombi has the potential to increase patient throughput at practicing offices by decreasing time spent eye dropping patients, eliminating time wasted waiting between drop instillations and ensuring more accurate drug delivery. The proposed study hopes to demonstrate the non-inferiority of using MydCombi to achieve pupillary dilation in patients compared to standard of care eye drops.

Key Details

Gender

All

Age Range

2 Years - Any

Study Type

INTERVENTIONAL

Enrollment

100

Start Date

2024-09-30

Completion Date

2024-12-31

Last Updated

2024-09-19

Healthy Volunteers

No

Interventions

DEVICE

MydCombi Device

ophthalmic spray

DRUG

MydCombi Drug

Tropicamide 1% and phenylephrine HCl 2.5%

Locations (1)

University of California, San Francisco

San Francisco, California, United States